SAN JOSE, Calif., October 25, 2023 -- Ensurge Micropower (OSE: ENSU, and OTCQB: ENMPY) (“Ensurge” or the “Company”), today announces it has signed an agreement for its solid-state lithium microbattery technology that extends its growing roster of strategic partnership engagements into the medical-device industry. The solid-state lithium microbattery technology is being similarly evaluated by six other manufacturers and the company remains on track to enter volume production by the end of the year.
“This latest agreement with a leading Fortune 500 medical-device manufacturer opens up yet another market opportunity for our unique battery technology,” said Lars Eikeland, CEO at Ensurge. “The agreement will also demonstrate how our microbattery can help transform wearable or portable medical device design by providing a safe, reliable and more energy-dense power source that has faster charging and a more flexible form factor compared to today’s alternatives. In addition to these breakthrough capabilities and improved cycle life, our solid-state lithium microbatteries will also be the first that can be assembled directly onto a product’s Printed Circuit Board using an industry-compatible automated Surface Mount Technology (SMT) process.”
About Ensurge Micropower
Ensurge is Energizing Innovation™ with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Contact
Investor Relations
E-mail: IR@ensurge.com
Lars Eikeland, CEO at Ensurge
E-mail: lars.eikeland@ensurge.com
